-
公开(公告)号：US10988535B2
公开(公告)日：2021-04-27
申请号：US16419938
申请日：2019-05-22
发明人： Kent B. Thudium , Mark J. Selby , Kyra D. Zens , Mark Yamanaka , Alan J. Korman , Heidi N. Leblanc
IPC分类号： C07K16/00 , A61K39/395 , C07K16/28 , A61K39/00
摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.
-
公开(公告)号：US20190276538A1
公开(公告)日：2019-09-12
申请号：US16419938
申请日：2019-05-22
发明人： Kent B. Thudium , Mark J. Selby , Kyra D. Zens , Mark Yamanaka , Alan J. Korman , Heidi N. Leblanc
IPC分类号： C07K16/28
摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.
-
公开(公告)号：US11236165B2
公开(公告)日：2022-02-01
申请号：US17226624
申请日：2021-04-09
发明人： Kent B. Thudium , Mark J. Selby , Kyra D. Zens , Mark Yamanaka , Alan J. Korman , Heidi N. Leblanc
摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to WIC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.
-
公开(公告)号：US11236163B2
公开(公告)日：2022-02-01
申请号：US17226595
申请日：2021-04-09
发明人： Kent B. Thudium , Mark J. Selby , Kyra D. Zens , Mark Yamanaka , Alan J. Korman , Heidi N. Leblanc
摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.
-
公开(公告)号：US20190276539A1
公开(公告)日：2019-09-12
申请号：US16419940
申请日：2019-05-22
发明人： Kent B. Thudium , Mark J. Selby , Kyra D. Zens , Mark Yamanaka , Alan J. Korman , Heidi N. Leblanc
IPC分类号： C07K16/28
摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.
-
公开(公告)号：US20160222114A1
公开(公告)日：2016-08-04
申请号：US15098627
申请日：2016-04-14
发明人： Jennifer Marie MATARAZA , Andrea Van Elsas , Alan J. Korman , Edward L. Halk , Kent B. Thudium , Mark J. Selby , Timothy W. Sproul , Heidi N. Leblanc
IPC分类号： C07K16/28
CPC分类号： C07K16/2803 , A61K2039/505 , C07K16/2818 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/77 , C07K2317/92
摘要： The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
摘要翻译： 本发明涉及对BTLA特异性的结合化合物及其用途。 更具体地，本发明涉及识别人BTLA并调节其在癌症，炎性和自身免疫性疾病中的活性的完全人抗体。
-
公开(公告)号：US11530267B2
公开(公告)日：2022-12-20
申请号：US17544534
申请日：2021-12-07
发明人： Kent B. Thudium , Mark J. Selby , Kyra D. Zens , Mark Yamanaka , Alan J. Korman , Heidi N. Leblanc
摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to WIC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.
-
公开(公告)号：US11512130B2
公开(公告)日：2022-11-29
申请号：US17544542
申请日：2021-12-07
发明人： Kent B. Thudium , Mark J. Selby , Kyra D. Zens , Mark Yamanaka , Alan J. Korman , Heidi N. Leblanc
摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to MHC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.
-
公开(公告)号：US10155813B2
公开(公告)日：2018-12-18
申请号：US15098627
申请日：2016-04-14
发明人： Jennifer Marie Mataraza , Andrea Van Elsas , Alan J. Korman , Edward L. Halk , Kent B. Thudium , Mark J. Selby , Timothy W. Sproul , Heidi N. Leblanc
摘要： The present invention relates to binding compounds specific for BTLA and uses thereof. More specifically, the invention relates to fully human antibodies that recognize human BTLA and modulate its activity in cancer, inflammatory, and autoimmune disorders.
-
公开(公告)号：US11236164B2
公开(公告)日：2022-02-01
申请号：US17226609
申请日：2021-04-09
发明人： Kent B. Thudium , Mark J. Selby , Kyra D. Zens , Mark Yamanaka , Alan J. Korman , Heidi N. Leblanc
摘要： The present disclosure provides isolated monoclonal antibodies that specifically bind to LAG-3 with high affinity, particularly human monoclonal antibodies. Preferably, the antibodies bind human LAG-3. In certain embodiments, the antibodies bind both human and monkey LAG-3 but do not bind mouse LAG-3. The invention provides anti-LAG-3 antibodies that can inhibit the binding of LAG-3 to WIC Class II molecules and that can stimulate antigen-specific T cell responses. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. This disclosure also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which an anti-LAG-3 antibody is co-administered with at least one additional immunostimulatory antibody, is also provided.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.026 秒)
